drugset / Trial / NCT02872025
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
Phase 0
Active not recruiting
42 enrolled
Laura Esserman
Merck Sharp & Dohme LLC · collabModernaTX, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.
Timeline
- Start
- 2016-12-12
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 2 mg | Other |
| Subject | Pembrolizumab | Monoclonal antibody | 4 mg | Other |
| Subject | Pembrolizumab | Monoclonal antibody | 8 mg | Other |
| Subject | mRNA-2752 | Messenger RNA (mRNA) | 1 mg | Other |
| Subject | mRNA-2752 | Messenger RNA (mRNA) | 4 mg | Other |